Showing 691-700 of 7174 results for "".
DERM2020 Exhibitor Reaction: Brett Fair, EPI Health
https://practicaldermatology.com/conferences/dermatology-education-foundation-derm-2020/derm2020-exhibitor-reaction-brett-fair-epi-health/19847/Brett Fair of EPI Health, a DERM2020 exhibitor, tells us what he thinks of the new virtual meeting world and how DEF is dominating it for dermatology!DERM2020 Attendee Reaction: TJ Chao, MPAS, PA-C
https://practicaldermatology.com/conferences/dermatology-education-foundation-derm-2020/derm2020-attendee-reaction-tj-chao-mpas-pa-c/19846/TJ Chao, MPAS, PA-C from Atlanta, GA shares his thoughts on participating in DERM2020.Updates in Pediatric Dermatology
https://practicaldermatology.com/topics/psoriasis/updates-in-pediatric-dermatology/19733/2019 was bookended by the release of new treatment guidelines for pediatric skin disorders. Sheila Fallon Friedlander, MD, gives an overview of these developments and other hot topics in pediatric dermatology.DermWireTV: Meet Crown Aesthetics, Revance to Market Teoxane Fillers, Almirall Collaborates
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-meet-crown-aesthetics-revance-to-market-teoxane-fillers-almirall-collaborates/19719/On the heels of recent acquisitions, Crown Laboratories is reorganizing and rebranding as three divisions: Crown Aesthetics, Crown Beauty, and Crown Therapeutics. Revance gains immediate and exclusive rights to commercialize Teoxane’s RHA 2, RHA 3, and RHA 4 products, which include lidocaine. A fourPerspective: The ABD's Push for Subspecialty Certification in Mohs Surgery Will Fracture Dermatology
https://practicaldermatology.com/topics/skin-cancer-photoprotection/perspective-the-abds-push-for-subspecialty-certification-in-mohs-surgery-will-fracture-dermatology/20502/Will SC infringe on the rights of non-certified dermatologists to preform Mohs? Could it lead to reduced exposure to this and other surgical treatments for future dermatologists in training?Stirring the Pot: Cannabinoids and Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/stirring-the-pot-cannabinoids-and-atopic-dermatitis/20565/Cannabinoids are a diverse group of compounds that may hold significant therapeutic capabilities applicable to many areas of medicine, including dermatology.Focusing on Patient Education in Atopic Dermatitis
https://practicaldermatology.com/topics/practice-management/focusing-on-patient-education-in-atopic-dermatitis/20661/Patients of all ages have atopic dermatitis, and they seek education and support from their dermatologists.On Dosage and Diet: Isotretinoin 101
https://practicaldermatology.com/topics/general-topics/on-dosage-and-diet-isotretinoin-101/21445/Isotretinoin is one of the most essential agents in the treatment of acne, but dietary and dosage considerations must be made to maximize efficacy. Author:Joshua Zeichner, MDThe Growing Importance of Social Media for Dermatologists
https://practicaldermatology.com/topics/practice-management/the-growing-importance-of-social-media-for-dermatologists/21591/Dermatology practitioners must realize that social media is not just a tool for building relationships; it is also good for their businesses.DWTV Extra: Phase 3 Data on Roflumilast for AD, PsO
https://practicaldermatology.com/programs/practical-dermatology/dwtv-extra-phase-3-data-on-roflumilast-for-ad-pso/35925/Study investigator Melinda Gooderham, MD, talks about the Phase 3 trials of roflumilast cream 0.15% for adults and children down to age 6 with atopic dermatitis and roflumilast foam 0.3% for patients older than 12 with psoriasis of the scalp and body.